Manipal Health IPO: Eyes $1 Billion Listing in January 2026

Introduction to a Landmark Healthcare Listing

Manipal Health Enterprises Pvt. Ltd., backed by Singapore's state-owned investor Temasek, is preparing to file draft papers for an initial public offering (IPO) in January 2026. The company is targeting a fundraise of approximately $1 billion, an event that could become the largest public listing by a hospital operator in India. This move signals strong investor confidence in the country's rapidly growing healthcare sector and positions Manipal to potentially become the nation's most valuable listed hospital chain.

IPO Structure and Financials

The proposed IPO will consist of two main components: a fresh issue of shares worth ₹8,000 crore (approximately $152 million) and an offer for sale (OFS) by existing shareholders. The OFS will involve the sale of up to 43.23 million shares, which represents a 3.66% stake in the company. According to sources, the total issue size could be between ₹10,500 crore and ₹11,000 crore. The company is aiming for a valuation of up to $13 billion, with some estimates suggesting a range of $12 billion to $15 billion depending on market conditions at the time of the listing. Manipal may also consider a pre-IPO placement of shares worth as much as ₹1,600 crore, which would reduce the size of the fresh issue.

Use of Proceeds

The primary objective for raising capital through the fresh issue is to strengthen the company's balance sheet and fuel its expansion plans. A significant portion of the proceeds, estimated at around ₹8,000 crore, will be allocated towards the repayment of outstanding borrowings. The remaining funds will be used to finance inorganic growth opportunities, including funding the recent acquisition of Sahyadri Hospitals, and for general corporate purposes. This strategic allocation of capital is designed to reduce debt and provide the financial flexibility needed for future growth.

Key Stakeholders and Advisors

A consortium of prominent financial institutions is advising Manipal on this landmark offering. The lead bankers include Kotak Mahindra Capital Co., Axis Bank Ltd., and the Indian units of Goldman Sachs Group Inc., JPMorgan Chase & Co., and Jefferies Financial Group Inc. Other advisors on the potential offering include UBS Securities and DBS Bank Ltd. The OFS component will see several existing investors divesting a part of their stake. These include TPG, Temasek, Ammar Sdn. Bhd., Novo Holdings Invest Asia, Phoenix Bear Investments LLC, and Manipal Education and Medical Group India Pvt. Ltd.

Manipal's Aggressive Expansion Strategy

Manipal Health has established itself as one of India's most active healthcare consolidators. The company has expanded its footprint rapidly through strategic acquisitions. Its most notable recent move was the acquisition of Sahyadri Hospitals, Maharashtra's largest hospital chain. This expansion was supported by a $100 million financing facility from KKR & Co. in June 2025, a deal that temporarily paused IPO preparations to allow the company to finalize the acquisition. With a network of over 49 hospitals and more than 10,600 operational beds, Manipal has surpassed its peers to become the largest hospital chain in India by bed capacity.

Market Context and Industry Impact

The Manipal IPO is set to create a new benchmark for the Indian healthcare sector. If successful, Manipal will surpass Max Healthcare Institute, which currently holds a market capitalization of about $12 billion, to become the most valuable hospital chain in the country. The offering highlights the increasing investor appetite for Indian healthcare, a sector that has seen significant private and foreign investment from global firms like Blackstone and KKR. The last major hospital IPO in India was that of Dr Agarwal’s Health Care, which raised $150 million, making Manipal's planned offering significantly larger and more impactful for the market.

Conclusion and Forward Outlook

Manipal Health Enterprises' planned IPO is a pivotal moment for the company and the Indian capital markets. By aiming to raise $1 billion at a valuation of up to $13 billion, the listing is poised to unlock significant value for its shareholders and provide substantial capital for deleveraging and future growth. With the draft papers expected to be filed in January 2026, all eyes will be on this offering, which is anticipated to launch mid-year. The success of this IPO will not only solidify Manipal's position as a market leader but also reinforce the investment appeal of India's healthcare industry.